Who Generates Higher Gross Profit? Catalent, Inc. or Alkermes plc

Catalent, Inc. vs. Alkermes plc: A Battle of Gross Profits

In the competitive landscape of the pharmaceutical industry, Catalent, Inc. and Alkermes plc have been vying for dominance in gross profit generation over the past decade. From 2014 to 2023, Catalent consistently outperformed Alkermes, with an average gross profit nearly 75% higher. Notably, in 2022, Catalent's gross profit peaked at approximately $1.64 billion, marking a significant lead over Alkermes' $893 million. However, 2023 saw a surprising shift, with Alkermes surpassing Catalent for the first time, achieving a gross profit of $1.41 billion compared to Catalent's $1.06 billion. This unexpected turn raises questions about market dynamics and strategic shifts within these companies. As we look to 2024, with some data still pending, the competition remains fierce, and stakeholders are keenly observing how these industry giants will adapt and evolve.